These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38458776)
1. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors. Feola S; Hamdan F; Russo S; Chiaro J; Fusciello M; Feodoroff M; Antignani G; D'Alessio F; Mölsä R; Stigzelius V; Bottega P; Pesonen S; Leusen J; Grönholm M; Cerullo V J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458776 [TBL] [Abstract][Full Text] [Related]
2. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211 [TBL] [Abstract][Full Text] [Related]
3. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830 [TBL] [Abstract][Full Text] [Related]
4. CD4 Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929 [TBL] [Abstract][Full Text] [Related]
5. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863 [TBL] [Abstract][Full Text] [Related]
6. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V Elife; 2022 Mar; 11():. PubMed ID: 35314027 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558 [TBL] [Abstract][Full Text] [Related]
12. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines. Li WH; Su JY; Li YM Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514 [TBL] [Abstract][Full Text] [Related]
13. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
14. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
15. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312 [TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F Front Immunol; 2019; 10():1505. PubMed ID: 31333652 [TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820 [TBL] [Abstract][Full Text] [Related]
19. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]